

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Maurer et al.
Application Serial No.: 10/767,352
Filed: January 30, 2004
For: *Oral Compositions of Fenretinide Having Increased Bioavailability and Methods of Using the Same*

Confirmation No.: 4884
Group Art Unit: 1618
Examiner: Blessing M. Fubara

Date: January 26, 2009

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT DATED
JANUARY 15, 2009**

Sir/Madam:

This is responsive to the Notice of Non-Complaint Amendment dated January 15, 2009 and to the Office Action dated September 5, 2008. It is respectfully requested that this application be reconsidered in view of the following amendments and remarks presented herein.

It is not believed that any fee(s), including fees for additional claims, are required, beyond those that may otherwise be provided for in documents accompanying this submission. In the event, however, that any requests, petitions or extensions of time for the accompanying response are required to prevent abandonment of this application, Applicants submit that such an extension is also hereby petitioned for under 37 C.F.R. §1.136(a) and/or a request be granted pursuant to 37 C.F.R. §1.114. Any additional fees believed to be due in connection with this submission may be charged to our Deposit Account No. 50-0220, or any overpayment may be credited to the same.

Amendments to the Specification begin on page 2 of this document.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this document.

Remarks begin on page 6 of this document.